Below are the financial statements of DiaSorin, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of EUR | 2024 | 2023 |
|---|---|---|
| Revenues | 1,185.43a | 1,148.21a |
| Cost of sales | -403.73a | -407.02a |
| Gross profit | 781.7a | 741.19a |
| Sales and marketing expenses | -287.75a | -285.89a |
| Research and development costs | -91.57a | -90.95a |
| General and administrative expenses | -128.02a | -128.52a |
| Other operating income (expenses) | -16.04a | -19.57a |
| Non-recurring amount | -6.72a | -21.59a |
| Operating result (EBIT) | 258.33a | 216.26a |
| Financial income | 12.92a | 15.37a |
| Financial expense | -28.8a | -30.41a |
| Result before taxes | 242.45a | 201.22a |
| Income taxes | -55.39a | -42.71a |
| Net profit for the year | 187.06a | 158.51a |
| Including | — | — |
| Parent company shareholders’ interests in net profit | 188.11a | 159.85a |
| Minority interests in net profit | -1.05a | -1.34a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore DiaSorin’s data sources below and access millions more through our Disclosure Search.